Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seoul, Korea.
Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seoul, Korea.
Trends Endocrinol Metab. 2021 Jul;32(7):500-514. doi: 10.1016/j.tem.2021.04.008. Epub 2021 May 8.
Metabolic dysfunction-associated fatty liver disease (MAFLD) is a chronic condition characterized by hepatic fat accumulation combined with underlying metabolic dysregulation. Having evolved from the previous term of nonalcoholic fatty liver disease (NAFLD), the term MAFLD more closely implicates the presence of overweight/obesity, type 2 diabetes, or metabolic dysregulation as essential pathogenic factors, leading to better identification of individuals with this metabolic liver disease. Low-grade inflammation, increased oxidative stress, mitochondrial dysfunction, and intestinal dysbiosis are also involved in its pathogenesis. MAFLD is not only associated with liver-related complications, but also with adverse cardiometabolic outcomes. Further studies are needed to assess whether the newly proposed definition of MAFLD is more accurate than the NAFLD in predicting the adverse liver-related and extrahepatic outcomes.
代谢相关脂肪性肝病（MAFLD）是一种慢性疾病，其特征是肝内脂肪堆积合并潜在的代谢紊乱。该术语源自先前的非酒精性脂肪性肝病（NAFLD），MAFLD 这一术语更紧密地暗示超重/肥胖、2 型糖尿病或代谢紊乱是基本的致病因素，从而更好地识别出患有这种代谢性肝病的个体。低度炎症、氧化应激增加、线粒体功能障碍和肠道菌群失调也参与其发病机制。MAFLD 不仅与肝脏相关并发症有关，还与不良的心血管代谢结局有关。需要进一步的研究来评估新提出的 MAFLD 定义是否比 NAFLD 更能准确预测不良的肝脏相关和肝外结局。
